XML 14 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 1,875 $ 963
Trade receivables 5,665 7,128
Inventories 4,866 4,924
Prepaid expenses 911 1,100
Other current assets 483 701
Assets held for sale 81 566
Total current assets 13,881 15,382
Deferred income taxes 427 574
Other non-current assets 722 932
Property, plant and equipment, net 7,101 7,673
Identifiable intangible assets, net 15,345 17,640
Goodwill 27,585 28,414
Total assets 65,061 70,615
Current liabilities:    
Short-term debt 2,673 3,646
Sales reserves and allowances 6,701 7,881
Trade payables 1,626 2,069
Employee-related obligations 712 549
Accrued expenses 2,232 3,014
Other current liabilities 886 724
Liabilities held for sale   38
Total current liabilities 14,830 17,921
Long-term liabilities:    
Deferred income taxes 2,478 3,277
Other taxes and long-term liabilities 1,803 1,843
Senior notes and loans 26,816 28,829
Total long-term liabilities 31,097 33,949
Commitments and contingencies, see note 16
Total liabilities 45,927 51,870
Teva shareholders' equity:    
Preferred shares of NIS 0.10 par value per mandatory convertible preferred share; September 30, 2018 and December 31, 2017: authorized 5.0 million shares; issued 3.7 million shares 3,825 3,631
Ordinary shares of NIS 0.10 par value per share; September 30, 2018 and December 31, 2017: authorized 2,495 million shares; issued 1,125 million shares and 1,124 million shares, respectively 54 54
Additional paid-in capital 23,404 23,479
Accumulated deficit (3,072) (3,808)
Accumulated other comprehensive loss (2,335) (1,848)
Treasury shares as of September 30, 2018 and December 31, 2017 - 106 million ordinary shares and 107 million ordinary shares, respectively (4,146) (4,149)
Stockholders' equity attributable to Teva shareholders 17,730 17,359
Non-controlling interests 1,404 1,386
Total equity 19,134 18,745
Total liabilities and equity $ 65,061 $ 70,615